CognitiveEV · ANIMAL

P21

Synthetic hexapeptide derived from CNTF (ciliary neurotrophic factor)

akaAc-DGGL(A)G-NH2Cerebrolysin-derived peptideCNTF analogue
Class
Nootropic peptide
Half-life
~10 min
Route
Intranasal
Cadence
Daily
Evidence
Animal data primarily

Overview

P21 is a synthetic six-amino-acid peptide (Ac-DGGL(A)G-NH2) designed as a short, stable fragment derived from ciliary neurotrophic factor (CNTF). The original rationale: CNTF promotes neuron survival and synaptic plasticity in animal models, but it's a large protein that doesn't cross the blood-brain barrier well and triggers harsh side effects when given systemically. P21 was engineered to retain some of CNTF's neurotrophic effects in a smaller, intranasal-deliverable package.

The peptide appears in research-market catalogues as a nootropic, with sellers claiming it enhances memory, learning, and neuroplasticity. The evidence base is almost entirely rodent studies — mostly Russian-language publications from the 2000s-2010s showing improved performance in Morris water maze and passive avoidance tests after intranasal dosing. There are no published human trials, no FDA/EMA regulatory filings, and no independent Western replications of the original Russian data.

Bottom line: P21 is a real peptide sequence with some published animal data supporting a cognitive effect, but the human evidence is zero and the animal data comes from a narrow source base. It's in a grey zone between 'legitimate research peptide with thin data' and 'research-market product with no real clinical grounding.'

Safety considerations

A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.

  • Not approved for human use by any regulator. No human safety trials published. All efficacy data are rodent-only.
  • No long-term toxicity studies in any species. The safety profile beyond 2-4 weeks of daily dosing is completely unknown.
  • Intranasal delivery bypasses the blood-brain barrier — this is the intended mechanism, but it also means systemic safety checks (liver metabolism, renal clearance) don't apply in the usual way. Unknown CNS accumulation risk.

+ 3 more safety notes inside AIx Core →

Commonly monitored

Markers and signals people track when researching P21.

  • Subjective cognitive changes — memory, focus, learning speed
  • Sleep quality (some users report vivid dreams or disrupted sleep)
  • Mood — irritability or anxiety if dosing too high
  • Nasal irritation or congestion from intranasal delivery
  • Neurological symptoms — headache, dizziness, any unusual sensory changes

Frequently asked questions

What is P21?

Synthetic hexapeptide derived from CNTF (ciliary neurotrophic factor). P21 is a synthetic six-amino-acid peptide (Ac-DGGL(A)G-NH2) designed as a short, stable fragment derived from ciliary neurotrophic factor (CNTF). The original rationale: CNTF promotes neuron survival and synaptic plasticity in animal models, but it's a large protein that doesn't cross the blood-brain barrier well and triggers harsh side effects when given systemically. P21 was engineered to retain some of CNTF's neurotrophic effects in a smaller, intranasal-deliverable package.

How is P21 administered?

Intranasal, typically daily.

What is the half-life of P21?

~10 min — Short plasma half-life; intranasal delivery targets CNS directly.

Is P21 approved for human use?

P21 is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.

What does the evidence show for P21?

Evidence tier: Animal data primarily. Shadurskaya 2006 (Russian) dosed 50-500 μg/kg intranasal in rats for 7 days; Morris water maze latency improved ~25-30% vs control. No Western replication.

What is commonly monitored when researching P21?

Commonly tracked markers + signals: Subjective cognitive changes — memory, focus, learning speed, Sleep quality (some users report vivid dreams or disrupted sleep), Mood — irritability or anxiety if dosing too high, Nasal irritation or congestion from intranasal delivery, Neurological symptoms — headache, dizziness, any unusual sensory changes.

Open this in AIx Core for the full picture

Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.